Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Randomized, Four-way Crossover Study in Healthy Male Subjects to Assess the Relative Bioavailability of Sorafenib Tablet for Oral Suspension Compared to Marketed Tablet and to Investigate the Pharmacokinetics of Sorafenib Tablet for Oral Suspension Including Food Effect and Dose Proportionality

Trial Profile

An Open Label, Randomized, Four-way Crossover Study in Healthy Male Subjects to Assess the Relative Bioavailability of Sorafenib Tablet for Oral Suspension Compared to Marketed Tablet and to Investigate the Pharmacokinetics of Sorafenib Tablet for Oral Suspension Including Food Effect and Dose Proportionality

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Chronic lymphocytic leukaemia; Gastric cancer; Head and neck cancer; Liver cancer; Myelodysplastic syndromes; Neuroendocrine tumours; Ovarian cancer; Renal cancer; Soft tissue sarcoma; Thyroid cancer
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 01 Sep 2017 Results assessing relative bioavailability of Sorafenib tablet for oral suspension compared to marketed tablet and to investigate the pharmacokinetics of Sorafenib tablet for oral suspension including food effect and dose proportionality, were published in the Clinical Pharmacology in Drug Development Conference: 2017 Annual Meeting of the American College of Clinical Pharmacology, ACCP 2017.
    • 03 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 11 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top